Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

NCT04683237 on ClinicalTrials.gov · last registry update 2024-09-26

Withdrawn before anyone was enrolled. Its estimated completion date, 30 November 2025, has passed with no update to the record. Primary outcome, as filed: Pathological complete response (CR) rates. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P2/P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Xiaojun Chen
Sponsor type: Other
Enrollment: 0
Started: 2021-03-20
Primary completion: 2025-11-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Pathological complete response (CR) rates

Conditions studied

Atypical Endometrial Hyperplasia · Obese · Fertility Issues

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.